Eton Pharmaceuticals, Inc. has recently acquired the U.S. commercialization rights to Hemangeol® (propranolol hydrochloride) oral solution. This acquisition marks a significant expansion of the company's rare disease portfolio, as Hemangeol is the only FDA-approved treatment for infantile hemangioma requiring systemic therapy.
The company's CEO, Sean Brynjelsen, highlighted the importance of this acquisition, emphasizing the critical role Hemangeol plays in treating infantile hemangiomas. With the incorporation of Eton's patient support program, Eton Cares™, the company aims to broaden patient access to Hemangeol. This program includes a $0 co-pay initiative, demonstrating the company's commitment to improving patient access to essential treatments.
Eton Pharmaceuticals has now achieved its goal of ten commercial products, with the recent approval of Desmoda™ (desmopressin acetate) and the acquisition of Hemangeol's U.S. commercialization rights. This milestone reflects the company's progress towards building the largest rare disease portfolio in the United States.
Infantile hemangiomas, non-cancerous vascular tumors that typically appear in newborns, can lead to serious complications and require systemic therapy in severe cases. Hemangeol is typically initiated between the ages of five weeks to five months and continues for approximately six months, with an estimated 5,000-10,000 infants treated with Hemangeol annually in the United States.
The transaction is expected to be accretive to 2026 earnings and will be financed with the company's cash on hand. Effective May 1, Eton will assume the commercialization of Hemangeol in the U.S., while Pierre Fabre will continue to commercialize Hemangeol globally and in the U.S. until April 30.
As a result of these announcements, the company's shares have moved -1.75% on the market, and are now trading at a price of $15.14. For more information, read the company's full 8-K submission here.
